We have shown that decreased bioavailability of EPC in malaria patients is due, in part, to heme toxicity, mediated by expression of TLR4 and further exacerbated by an exaggerated host inflammatory response due to excess production of CXCL10. The gene discussed is CXCL10; the disease is malaria.